About Fludarabine Phosphate Injection USP
Discover sublime savings with Fludacel 50, a formidable Fludarabine Phosphate Injection USP, designed for the unassailable treatment of B-cell chronic lymphocytic leukemia (CLL) in adults. This affordable, allopathic, medicine-grade solution offers a potent 50mg dose per vial, ensuring therapeutic efficacy. Its lyophilized powder form preserves maximal potency, and reconstitution is required for IV use. Recommended strictly under physician guidance, Fludacel 50 delivers steadfast performance, making it a bargain for both healthcare professionals and patients. Carefully packaged and manufactured in India, this single-use, prescription-required vial guarantees quality and patient safety.
Commercial Utility and Distinct Features
Fludarabine Phosphate Injection USP excels in commercial healthcare settings for treating B-cell CLL in adults. Its precise formulation and single-use vial design minimize wastage and ensure optimal dosing. The product also finds application in specialized oncological regimens, supported by robust clinical data. Manufactured to medicine-grade standards, this lyophilized powder form extends shelf life, maximizing usage. Fludacel 50's affordability and reliability render it a preferred choice for clinics, hospitals, and cancer care centers.
Express Delivery and Packaging Assurance
Fludacel 50 is dispatched with full assurance through express shipping, ensuring timely arrival at your facility. Each single-use vial comes securely packed in a box, meticulously protected during transit to maintain efficacy until sale. With India as its origin and a sale price reflecting genuine value, our supply chain supports consistent, on-demand availability in quantity per box of 1 vial. Track delivery and anticipate seamless replenishment, meeting the highest standards in hospital and pharmacy logistic requirements.
FAQ's of Fludarabine Phosphate Injection USP:
Q: How should Fludarabine Phosphate Injection USP be administered?
A: This medication is administered intravenously (IV) after reconstitution, as prescribed by a qualified physician. The proper dosage and administration schedule are tailored to the individual patient's needs.
Q: What is the main indication for Fludacel 50?
A: Fludacel 50 is indicated for the treatment of B-cell chronic lymphocytic leukemia (CLL) in adults, providing a potent option as part of anticancer chemotherapy regimens.
Q: When should the injection be used?
A: The injection should be used strictly when prescribed by a healthcare professional, following diagnosis and medical evaluation for B-cell CLL.
Q: Where should Fludacel 50 be stored for optimal preservation?
A: Store Fludacel 50 below 25C in a secure location, away from direct sunlight and moisture, as instructed on the packaging. Always check expiry before use.
Q: What are the commercial benefits of using this injection in healthcare settings?
A: Healthcare providers benefit from its precise dosing, single-use vial design, extended shelf life, and affordable pricing, making it a cost-effective and reliable option for cancer treatment.
Q: What is the process for preparing the injection for administration?
A: The lyophilized powder must be reconstituted with an appropriate solvent before IV administration. Detailed mixing instructions are provided in the accompanying product insert.